# A Study of TAK-505 in Adults With Solid Tumors

Source: https://onco.cc/trials/nct07436728/  
OnCo record `nct07436728` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TAK-505 in advanced solid tumours, run by Takeda, now recruiting.

## Summary

A Study of TAK-505 in Adults With Solid Tumors is a phase 1/2 interventional study registered as NCT07436728 by Takeda, with 151 participants planned, started 2026-05-11 and due to reach its primary completion in 2030-08-18. Interventions recorded: TAK-505.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07436728
- Phase: 1/2
- Setting: A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
- Sponsor: Takeda
- Enrolled: 151

## Sources

- ClinicalTrials.gov NCT07436728: https://clinicaltrials.gov/study/NCT07436728

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct07436728.json